These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2557300)

  • 1. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Berman ML
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; Yordan E; Beecham J
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
    Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE
    Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
    Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
    Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB; Salmon SE; Fleming TR
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
    Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
    Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
    Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
    Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
    Hochster H; Hunt M; Green M; Parkinson D; Smith T
    Invest New Drugs; 1990 Aug; 8(3):329-32. PubMed ID: 2272773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
    Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
    Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
    Rozencweig M; Crespeigne N; Kenis Y
    Invest New Drugs; 1983; 1(4):309-13. PubMed ID: 6678877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.
    Green MD; Speyer JL; Wernz JC; Colombo N; Beller U; Muggia FM; Beckman EM
    Invest New Drugs; 1990 Aug; 8(3):333-6. PubMed ID: 2272774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
    Fiore J; Kemeny N; Raymond V; Young C
    Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
    [No Abstract]   [Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Rose PG; Blessing JA; Lele S; Abulafia O
    Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer.
    Falkson G; Vorobiof DA
    Invest New Drugs; 1986; 4(2):165-9. PubMed ID: 3733376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
    Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
    Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis.
    Eitan R; Fishman A; Meirovitz M; Goldenberg H; Amit A; Koren C; Schneider Y; Rosengarten O; Neuman A; Keren-Rosenberg S; Safra T
    Anticancer Drugs; 2014 Jan; 25(1):101-5. PubMed ID: 24263191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group.
    van Oosterom AT; Aapro MS; Carnino F; van der Burg ME; Pecorelli S; Rotmensz N; Dalesio O; Vermorken JB
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1379-80. PubMed ID: 3181261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.